about
Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterationsObinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibodyMonoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.TP53 mutation and survival in chronic lymphocytic leukemia.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibComplex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.MYC stimulates EZH2 expression by repression of its negative regulator miR-26aIdelalisib and rituximab in relapsed chronic lymphocytic leukemiaPostibrutinib outcomes in patients with mantle cell lymphoma.Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphomaMDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysisQuantitative analysis of DNA methylation in chronic lymphocytic leukemia patients.Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia and 13q14: miRs and more.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells.Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemiaInteractions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.Advances in treating chronic lymphocytic leukemiaEvolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemiaDown-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia.Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes.Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskTranslocation t(X;11)(q13;q23) in B-cell chronic lymphocytic leukemia disrupts two novel genes.Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia.Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B.Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism.
P50
Q24598248-2B0148C6-B284-4F72-92CB-24ACBC969D51Q27027620-D74FB0DA-3FAF-4E7F-9E21-1A3690511796Q27851444-F2FBA0EC-8DD3-43B6-B2E5-CFE613DB0CB3Q27851577-05A08852-A647-461B-A277-9E5AD73B1071Q27853011-604B9B24-C54D-45AE-8747-6410CE227B38Q27853387-D15CB126-7D83-40C7-9933-F58256730292Q28291303-6576546C-1769-4589-9924-A9BD80F61C77Q28306347-488996EA-9DF4-452D-BC71-77CC34285ABCQ30277756-806E58AA-2C69-4435-B20D-242CFA8D3176Q30279207-D0F0AFE8-B934-48A8-9D80-668879F8B004Q30371806-6D539199-DB55-4D40-AE1F-F07172C93984Q30840070-826B9715-0094-4B88-960C-959A47849210Q31076515-13F1A5F9-47C3-4E3F-9D37-AC0FC391D8F2Q33368885-000B8E4B-8E1E-4736-BEB8-7864F9B39EADQ33385371-F9DFC1A3-48C3-407F-8854-E6EB639CE603Q33394947-15FE631C-3FE8-4E3B-824B-04B98389008BQ33396737-6081BACB-4652-4103-8004-0CDE789D5E3EQ33396918-632C56AF-C57A-46FD-A1DD-7F51C76244CCQ33402713-E2F066EB-9A41-4F51-B837-B0F0694647D2Q33417548-2C25E0F7-3040-4479-A0AB-7B3C98183D9EQ33419843-F63A7C4D-FB56-41B8-83FB-637947912327Q33426999-28230850-AA80-41D2-82B6-CD9D943E9CBFQ33429161-268EBE53-597D-4471-8DFC-29E910237DA0Q33432228-260C3DFA-C85B-4A32-A218-C20A4EAF109DQ33434270-2247A300-B16C-43AC-A99D-1DAA98A2C015Q33494799-01161393-D4BD-46DC-A3B8-9105925C88A4Q33573515-36B8D1CA-1160-4665-9958-42CD98E2EFA6Q33587644-6A9C64E6-3B01-489E-97A8-024DA0BC1226Q33695990-27A526E3-F648-4844-BAED-0A16CA9606A2Q34019917-4971F9A6-7886-4237-A2F5-69455B6B3CD5Q34052080-BF0D03B5-A4F4-46F1-BD4D-7994C63808C8Q34128395-29FD18B2-C587-48E7-B5CE-E1ECCEF0BFF9Q34130791-ED1FC7BE-BF5D-4F37-9ADC-5BADE3FBD33BQ34255118-3A838614-ECE8-4CB6-A81A-25ABFF62719CQ34367685-83CE5E9B-B542-420D-AB81-F08A7C9116DEQ34418874-DF115AEA-4AE4-4C58-9829-8B5516EF7C22Q34576292-BF807E09-6694-4B05-9F88-095A2EEF09ABQ34617307-F6F82E81-4C04-4629-BE74-D4CF778CB3E1Q34621297-E1DBD10E-3A28-4444-BBE3-31C798E854F6Q34650812-BAAE1C0A-DCEF-4421-993B-8171A4E556FF
P50
name
Stephan Stilgenbauer
@ast
Stephan Stilgenbauer
@en
Stephan Stilgenbauer
@es
Stephan Stilgenbauer
@fr
Stephan Stilgenbauer
@nl
type
label
Stephan Stilgenbauer
@ast
Stephan Stilgenbauer
@en
Stephan Stilgenbauer
@es
Stephan Stilgenbauer
@fr
Stephan Stilgenbauer
@nl
prefLabel
Stephan Stilgenbauer
@ast
Stephan Stilgenbauer
@en
Stephan Stilgenbauer
@es
Stephan Stilgenbauer
@fr
Stephan Stilgenbauer
@nl